Literature DB >> 3069410

Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone.

T Matsuyama1, R Komatsu, M Namba, N Watanabe, H Itoh, S Tarui.   

Abstract

Glucagon-like peptide-1 (GLP-1) (1-37) and the fraction derived from it, GLP-1 (7-36 amide), are peptides encoded by the preproglucagon gene and possibly co-secreted with enteroglucagon. When added at a 25-nM concentration, GLP-1 (7-36 amide) decreased the release of glucagon from the perfused rat pancreas from 68.5 +/- 9.0 pg/ml to 41.5 +/- 11.5 pg/ml at 2 min in the presence of 11.2 mM glucose (P less than 0.01), and from 196.0 +/- 32.5 pg/ml to 87.0 +/- 23.5 pg/ml at 5 min in the presence of 2.8 mM glucose (P less than 0.05). Insulin levels increased from 12.6 +/- 3.0 microU/ml to 48.9 +/- 14.0 microU/ml at 10 min in the presence of 11.2 mM glucose (P less than 0.05) and from 2.0 +/- 0.4 microU/ml to 8.2 +/- 2.3 microU/ml at 2 min in the presence of 2.8 mM glucose (P less than 0.05). Glucagon and insulin release were not affected significantly by GLP-1 (1-37), irrespective of glucose concentration. We suggest that GLP-1 (7-36 amide) rather than enteroglucagon may be the true physiologic gut hormone and that it may act as 'incretin' in the enteroinsular axis. We suggest further that the glucagonostatic and insulinotropic activities of this peptide are unique and might be important in islet-cell function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069410     DOI: 10.1016/s0168-8227(88)80063-9

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  16 in total

1.  Multivalent activation of GLP-1 and sulfonylurea receptors modulates β-cell second-messenger signaling and insulin secretion.

Authors:  Nathaniel J Hart; Craig Weber; Klearchos K Papas; Sean W Limesand; Josef Vagner; Ronald M Lynch
Journal:  Am J Physiol Cell Physiol       Date:  2018-11-07       Impact factor: 4.249

Review 2.  Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Authors:  B E Dunning; J E Foley; B Ahrén
Journal:  Diabetologia       Date:  2005-08-13       Impact factor: 10.122

Review 3.  A review of the efficacy and safety of oral antidiabetic drugs.

Authors:  Stephanie Aleskow Stein; Elizabeth Mary Lamos; Stephen N Davis
Journal:  Expert Opin Drug Saf       Date:  2012-12-14       Impact factor: 4.250

4.  New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

Authors:  Baptist Gallwitz
Journal:  Rev Diabet Stud       Date:  2005-08-10

5.  Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.

Authors:  Luba Yammine; Charles E Green; Thomas R Kosten; Constanza de Dios; Robert Suchting; Scott D Lane; Christopher D Verrico; Joy M Schmitz
Journal:  Nicotine Tob Res       Date:  2021-08-29       Impact factor: 4.244

6.  Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes.

Authors:  Peggy Soule Odegard; Anthony Desantis
Journal:  Diabetes Metab Syndr Obes       Date:  2009-07-31       Impact factor: 3.168

7.  Understanding the cardiovascular effects of incretin.

Authors:  Ji Sung Yoon; Hyoung Woo Lee
Journal:  Diabetes Metab J       Date:  2011-10-31       Impact factor: 5.376

8.  The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.

Authors:  Emil Egecioglu; Jörgen A Engel; Elisabet Jerlhag
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

Review 9.  Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

Authors:  Thomas Forst; Matthias M Weber; Andreas Pfützner
Journal:  Exp Diabetes Res       Date:  2012-04-17

10.  The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice.

Authors:  Emil Egecioglu; Jörgen A Engel; Elisabet Jerlhag
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.